Islet Sciences to take over DiaKine Therapeutics
According to the agreement, the company has agreed to issue an aggregate of 200,000 shares of its newly designated shares of Series C preferred stock in exchange for
Isomorphic Labs has raised $5bn in a Series C financing round to support the development of its AI platform and advance its therapeutic candidates towards clinical evaluation.
The company has gained an exclusive, worldwide license to intellectual property surrounding the tumor-associated antigen mesothelin, which is highly expressed in pancreatic cancer, ovarian cancer and mesothelioma. The